Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06940440 · ClinicalTrials.gov registry record · Phase 1
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
A Phase 1 study of Advanced Or Metastatic Merkel Cell Carcinoma, sponsored by TuHURA Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 2
- Study locations
NCT06940440 is a Phase 1 study of Advanced Or Metastatic Merkel Cell Carcinoma that is actively recruiting participants, run by TuHURA Biosciences. The registered enrollment target is 9 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06940440, a Phase 1 study of Advanced Or Metastatic Merkel Cell Carcinoma, is actively recruiting participants, sponsored by TuHURA Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 2
- Study locations
Study Summary
This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult patients (≥18 years) with non-cutaneous Merkel Cell Carcinoma. Nine subjects will receive IFx-Hu2.0 as a visceral lesion injection in a single lesion followed by pembrolizumab.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG IFx-Hu2.0
Study Locations (2)
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2025-10 |
| Est. Completion | 2028-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06940440
The ClinicalTrials.gov registry entry for NCT06940440 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TuHURA Biosciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Or Metastatic Merkel Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06940440 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06940440 about?
NCT06940440 is a clinical study titled "IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)". This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult patients (≥18 years) with non-cutaneous Merkel Cell Carcinoma. Nine subjects will receive IFx-Hu2.0 as a visceral lesion injection in a single lesion follow...
What is the current status of trial NCT06940440?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2025-10. Estimated completion is 2028-05-31.
What conditions does trial NCT06940440 study?
This clinical trial studies the following conditions: Advanced Or Metastatic Merkel Cell Carcinoma.
What interventions are being tested in trial NCT06940440?
The interventions under investigation include: Pembrolizumab (DRUG), IFx-Hu2.0 (DRUG).
Who is sponsoring clinical trial NCT06940440?
This trial is sponsored by TuHURA Biosciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06940440 being conducted?
This trial has 2 study locations across Florida, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Or Metastatic Merkel Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.